DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Anlotinib is an investigational drug.
There have been 151 clinical trials for Anlotinib. The most recent clinical trial was a Phase 2 trial, which was initiated on June 26th 2019.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Carcinoma. The leading clinical trial sponsors are Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, and Sun Yat-sen University.
There are seven US patents protecting this investigational drug and fifty-eight international patents.
Recent Clinical Trials for Anlotinib
|TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer||Dong Wang||N/A|
|Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma: a Randomised Phase 3 Trial||Sun Yat-sen University||Phase 3|
|Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer||Shanghai Zhongshan Hospital||Phase 2|
Top disease conditions for Anlotinib
Top clinical trial sponsors for Anlotinib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Anlotinib||Start Trial||Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)meth- yl)cyclopropanamine, its crystalline form and its salts||Advenchen Pharmaceuticals, LLC (Moorpark, CA)||Start Trial|
|Anlotinib||Start Trial||Methods and uses of quinoline derivatives in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same||Start Trial|
|Anlotinib||Start Trial||Method for treating tumour, pharmaceutical composition and medicinal kit||Start Trial|
|Anlotinib||Start Trial||Quinoline derivative against non-small cell lung cancer||Start Trial|
|Anlotinib||Start Trial||Spiro substituted compounds as angiogenesis inhibitors||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|